The Signal
Conviction is crystallizing around AI-augmented biotech as the next leg higher, while traditional crypto and mega-cap tech are tagged as overvalued or structurally challenged. Two distinct trader archetypes are rotating: @crypto_condom is rotating out of Bitcoin (sees $STRC as a warning bell, targets $42–52K) and into biotech; @biotech2k1 is liquidating bubble positions ($MSFT, $META, $MIRM) and building fortress portfolios in undervalued markets (South America, Asia). The macro read is unified: equities have vampired crypto, and sentiment is pivoting toward unsexy, fundamental-driven value.IMPORTANT
AI's clinical impact (screening, grading, early detection) is already live in cardiology, oncology, urology—this isn't speculation.
What's Moving
- $ABCL, $IOVA, $ABSI — AI-biotech thesis; $ABSI is a trade, $ABCL and $IOVA are 2–3 year holds (via @crypto_condom)
- $MELI, $NU, $DLO, $INTR — South American fundamentals rated 8–9/10 across valuations ($12–$2,500); $DLO draws 80% revenue from Brazil/Mexico/Argentina (via @biotech2k1)
- $SE, $HASI — Asia portfolio build; $SE is already top-5 pick, $HASI next deep-dive target (via @biotech2k1)
- Bitcoin $42K–$52K — downside target as ETF outflows persist (−$140M this week) and equities outpace crypto returns 2x–10x (via @crypto_condom)
- $STRC / $MSTR — structural red flags; dividend reserves depleting, forced dilution or BTC liquidation coming (via @crypto_condom)
Crosscurrents
- Biotech enthusiasm vs. valuation risk — @crypto_condom is bullish on AI-biotech thesis but $ABSI is flagged as a trade (not hold), implying near-term profit-taking risk. Conviction may not extend to IPO-stage or pre-revenue names.
- South America micro-cap concentration — @biotech2k1's $DLO, $INTR thesis is fundamental-heavy but liquidity and geopolitical tail risks (Argentina, Brazil macro) are not addressed.
- Bitcoin technicals unclear — @crypto_condom expects $42K but is watching $STRC behavior; if $STRC rallies on Saylor buying, BTC could gap higher (contradicts bearish case).
Tradecraft
BULL
AI-biotech showing early clinical wins in real-time (CTA flagging, cardiac MRI inflammation detection, DBT screening). First-mover biotech + AI-enabled detection could command premium multiples if clinical evidence firms up.
BEAR
Bitcoin momentum is breaking on equity outperformance and MSTR/STRC structural stress. If Saylor is forced to sell BTC to service dividends, downside to $42K is real. ETF outflows haven't reversed.
WATCH
$STRC ex-dividend behavior and Saylor insider activity. Bitcoin's break below $60K on elevated NQ strength. Biotech earnings (IOVA, ABCL) confirmation of AI adoption in clinical workflows.
Desk Notes
- @crypto_condom — Rotating from Bitcoin into AI-biotech ($ABCL, $IOVA, $ABSI); sees $STRC as systemic risk; targets BTC downside $42–52K unless price competes with semi/AI equity returns.
- @biotech2k1 — Liquidating bubble tech ($MSFT, $META), building 4-stock fortress per region (South America done, Asia in progress); holding $SE as top Asia pick, hunting undervalued fundamentals in non-bubble pockets.
- @adamfeuerstein — Covering UniQure/Huntington's disease clinical narrative; amplifying AI's real role in cardiology and oncology screening (supporting the biotech-AI thesis).